past ees events
March 22nd, 2016 8:30-10:00AM OBIO invites you to join us for this exceptional members-only opportunity to learn from Ela Borenstein, Managing Partner, BDC Capital Healthcare Venture Fund and Ihor Boszko, Vice President, Business Development, Xagenic on how to prepare for the due diligence process to successfully close your financing!
Mar 2, 2016 OBIO invites you to join us for the first in a series of unique Pre-CAAP workshops throughout 2016 designed for companies that are in the process of raising or will have raised “seed” or later rounds of financing by the end of 2016 and may apply for the next cycle of OBIO CAAP.
OBIO will hold an information session on Pre-CAAP by webinar February 1st, 2016 at 12 noon. Click here to register and obtain login details.
Review the Top Five Valuation Methods for early-stage bioscience companies seeking financing, with Gregory Phipps, Managing Director of Innovacorp.
Learn about the latest developments related to the Canadian Scientific Research and Experimental Development Tax Incentive Program. The work shop will be lead by experts Bob Singh - Partner Tax Services, & Greg Garland – Partner SR&ED Tax Incentive Services, and Mel Machado – National SR&ED.
Attract and retain Angel Investors, and understand the importance of investor relations for private bioscience companies. Gain other key insights into corporate structures, securities pitfalls as well as other issues unique to angel-backed companies. Lead by Neil Klompass, CFO of Zymeworks.
Everything you want to know about the world of life science venture capital investing – and now you can ask! Gain perspective into what VC’s look for, why it’s important, and why this matters to early stage CEOs. Lead by Richard Meadows, Life Sciences investment expert and managing partner at Canadian venture capital investor CTI Life Sciences Fund.
OBIO would like to invite you to join us for an exclusive workshop focused on The Pan Canadian Pricing Alliance (pCPA). The pCPA conducts joint provincial/territorial negotiations for brand name drugs in Canada to achieve greater value for publicly funded drug programs and patients. This workshop will be valuable to all therapeutics companies.
Topics will include:
• What is pCPA and how will it affect therapeutic pricing in Canada?
• What have been the outcomes of pCPA reviews to date?
• Where is pCPA going next?
Learn the fundamental terms and hidden traps in negotiating an equity financing with a VC investor. Valuable to all companies preparing to negotiate and secure investment.
Topics will include:
• Founders’ vesting and sale restrictions
• Liquidation preferences and conversion features
• Valuation and Anti-Dilution
• Pre-emptive rights
• Protective (i.e. consent right) provisions
• Liquidity events (e.g., ROFRs, piggy-backs, etc.)
Understand the importance of developing your clinical strategy early in the drug development process. This exclusive workshop is focused on Canadian and International Reimbursement Strategies and will be lead by Allan Miranda, Therapeutic Lead, Reimbursement and Market Access, and Lois Mitchell, Director, New Product Development with Janssen Pharmaceutical Companies of Johnson & Johnson.